## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report that tributyltin propionate (TBT-P) and tributyltin salicylate (TBT-S) bind to the retinoid X receptor alpha (RXRalpha) ligand binding pocket as predicted by docking, act as RXR agonists, and modulate transcriptional activity through an RXR-thyroid hormone receptor (TR) heterodimer in a reporter cell line, while showing no activity through the vitamin D(3) receptor (VDR) in a separate reporter cell line, consistent with a non-permissive RXR-VDR heterodimer model.
- **Visible evidence base** Docking results in RXRalpha (software specified as Schrodinger suite); reporter assay data in PZ-TR and IZ-VDRE cell lines; no quantitative data, statistical details, or experimental protocols provided in the abstract
- **Missing materials affecting confidence** Full methods, docking scores and validation metrics, dose-response curves, statistical analyses, positive and negative control data, compound purity and source information, and any structural or functional validation beyond the two reporter assays

## Reviewer
- **Overall assessment** The abstract presents a plausible hypothesis that two organotin compounds act as RXR agonists, supported by in silico docking and two cell-based reporter assays. However, the evidence as described is insufficient to establish the claims with confidence. The docking analysis lacks quantitative validation, and the reporter data are presented without numerical results, controls, or statistical assessment. The conclusion that these compounds are "novel RXR agonists" is not fully supported by the visible evidence, and the mechanistic interpretation regarding VDR non-permissiveness is inferred rather than directly demonstrated.
- **Who would be interested in the results, and why** Researchers in nuclear receptor biology, endocrine disruption toxicology, and environmental health would be interested, as organotin compounds are established environmental contaminants with known nuclear receptor activity. The findings could also be relevant to those studying therapeutic applications of RXR ligands or structure-activity relationships of organometallic compounds.
- **Major strengths** The study addresses a relevant and under-explored area of organotin toxicology by examining two specific compounds not previously characterized as RXR ligands. The use of two distinct reporter cell lines to assess heterodimer-specific activity is a reasonable experimental design. The combination of in silico and in vitro approaches is appropriate for an initial characterization.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality is moderate, as organotins are known RXR ligands, though the specific compounds are new. Scientific importance is limited by the lack of quantitative evidence and the narrow scope of functional characterization. Interdisciplinary readership is possible given the toxicology and nuclear receptor communities, but the abstract does not provide sufficient mechanistic depth to attract broad attention. Technical soundness cannot be fully assessed from the abstract alone, but the visible evidence is insufficient to support the central claims. Readability for nonspecialists is adequate, though the abstract assumes familiarity with nuclear receptor terminology and reporter assay systems.
- **Recommendation posture** Currently not established from the provided evidence. The claims require substantial additional data, including quantitative docking metrics, full dose-response and statistical analyses, and appropriate controls, before the case for novel RXR agonism can be considered supported.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that TBT-P and TBT-S "bind in the binding pocket of RXRalpha and represent novel RXR agonists" based on docking.
- **Evidence pointer** Abstract, docking description; location not provided
- **Concern** The docking analysis is described only qualitatively. No docking scores, binding energies, comparison to known ligands, or validation of the docking protocol are provided. The claim of binding is therefore not quantitatively supported.
- **Why it matters** A docking result without numerical metrics or comparison to established ligands cannot distinguish specific binding from non-specific or artefactual poses. The central claim of the paper depends on this in silico evidence.
- **Resolution test** Provide docking scores, RMSD values for protocol validation, and comparison with a known RXR agonist such as 9-cis-retinoic acid or bexarotene. Show that the compounds rank comparably to known ligands in the same docking setup.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that TBT-P and TBT-S "exert transcriptional activity under basal and ligand-activated conditions through RXR - TR heterodimer" in the PZ-TR cell line.
- **Evidence pointer** Abstract, PZ-TR reporter assay; location not provided
- **Concern** No quantitative data are presented. The abstract does not report effect sizes, dose-response relationships, statistical significance, or comparison to positive controls such as known RXR agonists. The phrase "exert transcriptional activity" is ambiguous without these details.
- **Why it matters** Transcriptional activity in a reporter assay can be weak, non-specific, or within noise. Without numerical results and statistical analysis, the claim of functional agonism is not verifiable.
- **Resolution test** Provide dose-response curves, EC50 values, maximal fold induction relative to vehicle and positive controls, and statistical tests for at least three independent experiments.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Interpretive validity
- **Claim pointer** The authors state that the lack of VDR transcriptional activity in IZ-VDRE is "in agreement with the properties of the non-permissive type of RXR-VDR heterodimer."
- **Evidence pointer** Abstract, IZ-VDRE reporter assay; location not provided
- **Concern** The absence of VDR activity is interpreted as evidence for non-permissive heterodimer behavior, but this interpretation requires demonstration that the compounds are indeed acting through RXR in the VDR assay context. Without a positive control showing RXR activation in the same cell line, the lack of VDR activity could be due to poor cell permeability, compound toxicity, or assay insensitivity.
- **Why it matters** The mechanistic conclusion about heterodimer permissiveness is a key interpretive claim. If not properly controlled, it overreaches the data.
- **Resolution test** Include a positive control RXR agonist in the IZ-VDRE assay to confirm that RXR activation alone does not drive VDR-mediated transcription. Also report cell viability data to exclude toxicity as a confound.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Terminology
- **Evidence pointer** Abstract, title and text; location not provided
- **Issue** The term "novel RXR ligands" in the title is broader than the evidence, which only addresses agonism in a reporter assay and docking. The abstract later specifies "agonists," but the title is imprecise.
- **Required correction** Revise the title to specify "agonists" rather than "ligands," or provide direct binding data to support the broader term.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Compound characterization
- **Evidence pointer** Abstract, compound names; location not provided
- **Issue** No information is given on compound purity, source, or concentration range used in the assays. This limits reproducibility.
- **Required correction** State the source, purity, and concentration range of TBT-P and TBT-S in the methods or abstract.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Interpretive caution
- **Affected element** Generalization
- **Evidence pointer** Abstract, concluding statement; location not provided
- **Issue** The conclusion that both compounds "represent new nuclear retinoid X receptor agonists" is stated categorically, but the evidence is limited to two cell lines and one in silico method. No data on other RXR isoforms or off-target receptors are provided.
- **Required correction** Soften the conclusion to indicate that the compounds act as RXR agonists in the tested systems, and note that broader receptor selectivity remains to be established.

## Risk / unsupported claims
- The claim that TBT-P and TBT-S "bind in the binding pocket of RXRalpha" is unsupported without quantitative docking metrics or experimental binding data.
- The claim that the compounds "represent novel RXR agonists" is not fully supported, as functional agonism is only shown in one reporter context without dose-response or statistical evidence.
- The interpretation of non-permissive RXR-VDR heterodimer behavior is unsupported without appropriate positive controls in the VDR assay.
- The title's use of "ligands" is broader than the evidence, which only addresses agonism in a limited context.